AGENDA AT A GLANCE

DAY 1
DAY 2

Scaling Next-Gen Biologics in DACH

Upstream Process Intensification
Industry Roundtables: Future of Biomanufacturing
Single-Use Technologies Versus Stainless Steel
Continuous Manufacturing
Automation & AI in Biologics Manufacturing
Advances in Downstream Processing
Scaling Platforms and Facilities for Future Modalities
Drink Reception
End of Conference
VIEW DAY 1
VIEW DAY 2

Day 1

11 February 2026

GO TO DAY 2

8:30

Registration & Coffee

Scaling Next-Gen Biologics in DACH

9:00

Opening Keynote: Advancing Personalizing vaccines for commercial success – moving towards phase 3

Simone Steiner | CTO, Transgene, Switzerland

9:25

Panel Discussion - Future of Biomanufacturing

Moderator

Uwe Buecheler | Senior Advisor, Biopharmaceuticals, Boehringer Ingelheim, Germany

Panelists

Simone Steiner | CTO, Transgene, Switzerland
Thomas Sauer | Head of Microbial Platform, Global CMC Development, Sanofi, Germany
Volker Huppert | Chief Development Officer, Glycostem, Germany

9:50

Reserved for Solution Provider

10:20

Networking Break

10:45

Roundtable Discussions

  • Enhancing the Efficiency of Technology Transfers
  • Mitigating Risks in cell therapy:
  • Optimizing Biomanufacturing Processes with Industry 5.0 Innovations
  • Addressing the Biopharma Talent Shortage - Is it possible to reduce the cost of ATMP in the future – for the benefit of the patients?
Mohamed S. Chtaini | Executive Director – Global Biologics External Collaborations & Manufacturing, Incyte, Switzerland
  • Stainless vs Disposable
Karoline Bechtold-Peters | Director Science & Technology, Novartis, Switzerland

11:45

Key Takeaways

12:00

Lunch Break

Continuous/Intensified Manufacturing

13:00

Panel Discussion

Practical Strategies for Implementing Continuous Manufacturing in Facilities

Max Corbett, Senior Director, CMC Group Head Biologics and Small Molecule, CSL, Switzerland

13:25

Reserved for Solution Provider

Andreas Schaaf | Managing Director / CSO, Eleva, Germany

13:50

Presentation topic

14:30

Networking Break

Advances in Downstream Processing

15:00

Process Development using high throughput technology and modelling approach

Cecile Brocard | Head of Downstream Development, Boehringer Ingelheim, Austria

15:25

TBC

Karoline Bechtold-Peters | Director Science & Technology, Novartis, Switzerland

16:00

Roundtable Discussions

  • Upstream Intensification: What Works Best Across Modalities?
  • Implementing Continuous Manufacturing: Hype vs. Reality
Dennis Stelljes | Associate Director, Strategic Sourcing & Procurement, Biologics External Manufacturing BMS, Switzerland
  • Digital Maturity in Biomanufacturing: Where Are We, really?
  • Biomanufacturing Facility of the Future: Standardized, Flexible, or Both?
  • Sustainable Biomanufacturing: From Pilot to Practice

17:00

Key Takeaways

17:15

END OF DAY 1

Want to Speak at This Event?

Join the roster of esteemed colleagues to discuss what you or your company are bringing to the biopharmaceutical industry.

Apply to Speak

Day 2

12 February 2026

GO TO DAY 1

8:30

Registration & Coffee

Continuous Manufacturing

9:00

Implementing Perfusion Systems for High-Density Cell Culture

Gabriella Cotugno | Head of Vector Construction and Development, Nouscom, Italy

9:25

Panel Discussion - Breaking Down Regulatory and Organizational Barriers to Continuous Bioprocessing

9:50

Reserved for Solution Provider

10:20

Networking Break

Single-Use Technologies Versus Stainless Steel

10:45

Balancing Stainless Steel and Single-Use Systems in Modern Biomanufacturing Facilities

Mohamed S. Chtaini | Executive Director – Global Biologics External Collaborations & Manufacturing, Incyte, Switzerland

11:10

Reserved for Solution Provider

11:35

DACH Case Study: Choosing the Right Infrastructure for Long-Term Efficiency and Regulatory Readiness

12:00

Lunch Break

Automation & AI in Biologics Manufacturing

13:00

Application of Digital Twins in Biologics Development and Manufacturing

Thomas Sauer | Head of Microbial Platform, Global CMC Development, Sanofi, Germany

13:25

Driving Operational Excellence with AI Powered Decision Support in Biomanufacturing

14:15

Networking Break

Scaling Platforms and Facilities for Future Modalities

14:30

Smart Decision-taking with Facility Models Regarding Process Fit and Optimisation

Dr. Joachim Bär | Director Cell Culture Development, Boehringer Ingelheim, Germany

15:10

Future Proofing Facility Investments with Modular Design and Scalable Platforms

15:35

Roundtable Discussions

  • AI and Machine Learning in Bioprocess Optimization: First-Hand Use Cases
  • Platform Approaches for Biosimilars vs. Novel Biologics
  • Hybrid Manufacturing Models: Balancing In-House and CDMO Capabilities
  • Post-Approval Manufacturing Changes: Regulatory & Operational Impact
  • Cost Pressures in Biologics Manufacturing: Strategies for Lean Operations
  • Biomanufacturing KPIs: What Metrics Truly Matter?

16:30

Chairman’s Closing Rearks

16:30

END OF CONFERENCE

Get Your Ticket
View the 2025 Post-Event Report